Ionis, Suzhou Ribo deal

Ionis said it granted Suzhou Ribo Life Science commercialization rights in China to two antisense drug candidates in metabolic disease and cancer, with an option for a third candidate. Ionis received an undisclosed upfront payment and equity stake in Suzhou.

Ribo will also conduct a program to discover and identify candidates using Ionis' single-stranded RNAi technology. Ribo may opt to obtain local rights to each candidate, and would be responsible for development and commercialization. Ionis is eligible for milestones and royalties...